Kornimate/medical-research-clean huggingface dataset:
evaluation of low blood sugar events in participants with diabetes (mk-0431-401)

Conditions: Type 2 Diabetes Mellitus

Summary: this is a multi-center, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with type 2 diabetes mellitus (dm) who have been treated with sulphonylurea (su) monotherapy or su + metformin (mf) combination therapy by their cardiologist, nephrologist, neurologist, or family practice doctor for at least 6 months prior to study enrollment.


Eligibility criteria:
inclusion criteria: * participants diagnosed with type 2 dm. * participants at least 30 years of age at time of type 2 dm diagnosis. * participants treated with su monotherapy or su + mf combination therapy for at least 6 months prior to enrollment. * participants receiving diabetes care from a cardiologist, nephrologist, neurologist, or family practice doctor for at least 6 months. * participants with a clinical record in the health care center. * participants in whose medical records a minimum core data set can be found; core data defined as: age, gender, duration of diabetes/age at diagnosis, all glucose-lowering medications (branded and generic names, dosage, dosing frequency, starting and stopping dates) since the start of all antihyperglycemic medications. exclusion criteria: * participants with type 1 dm. * participants who are pregnant or with gestational dm. * participants receiving any anti-diabetic treatment from an endocrinologist/diabetologist in the previous 6 months. * participants requiring daily concomitant usage of insulin. * participants receiving any oral diabetes medications other than su or su + mf. * participants who are already participating in a clinical trial or other clinical study. * participants for whom it would be impossible to complete the questionnaire.
comparison of pulmonary vein isolation versus av nodal ablation with biventricular pacing for patients with atrial fibrillation with congestive heart failure (paba chf)

Conditions: Atrial Fibrillation; Congestive Heart Failure

Summary: for patients with atrial fibrillation and heart failure, current treatment can include av nodal ablation with biventricular pacing. pulmonary vein isolation (pvi) is a new procedure for this patient population which attempts to restore sinus rhythm. this trial is a randomized controlled trial of avn ablation with biventricular pacing versus pvi for atrial fibrillation patients with congestive heart failure.


Eligibility criteria:
inclusion criteria: * patients with symptomatic atrial fibrillation with nyha ii-iii symptoms despite the use of anti-arrhythmic medications. * ejection fraction was required to be ≤ 40%. * patients were required to be on a heart failure regimen that included beta-blockers and ace-inhibitors or angiotensin receptor blockers for all patients and spironolactone for nyha iii patients. * patients were required to complete a 6-minute walk test and to be ≥ 18 years of age. exclusion criteria: * reversible causes of af and heart failure (hf) such as pericarditis, hyperthyroidism, valvular heart disease and tachycardia-induced cardiomyopathy. * post-operative af, previous maze or maze-like surgery, previous left atrial instrumentation * life expectancy ≤ 2 years * likely cardiac transplant within the next 12 months * contraindication to anti-arrhythmic medications and/or anticoagulation * severe pulmonary disease * documented intra-atrial thrombus * tumor or other abnormalities which preclude catheter introduction * cardiac surgery, mi or pci within the past three months.
getting smart for pediatric epilepsy

Conditions: Epilepsy in Children

Summary: the purpose of this study is to evaluate the effect of melatonin for improving sleep in pediatric epilepsy.

sleep disturbances are more prevalent in children with epilepsy whose sleep can be disrupted by seizures occurring during the night and/or during the day. melatonin is a naturally occurring hormone produced in the pineal which regulates sleep-wake cycles and facilitates quality sleep. therefore, the purpose of this study is to evaluate the effect of melatonin for improving sleep in pediatric epilepsy.

Eligibility criteria:
inclusion criteria: - children aged between 1 and 18 years with a confirmed diagnosis of epilepsy and with sleep problems exclusion criteria: * children who are bedridden with limited mobility * children with liver or kidney dysfunction * children on medication for sleep or mood problems within 4 weeks before the baseline clinic visit * adolescent girls who are pregnant or breastfeeding * adolescent girls who have sexual activities but cannot take effective contraceptive measures during the trial
improving maximal strength in the initial postoperative phase after anterior cruciate ligament reconstruction surgery: randomized controlled trial of an app-based serious gaming approac

Conditions: Anterior Cruciate Ligament Rupture

Summary: the investigators designed a prospective randomized trial to evaluate whether an app based active muscle training program (genusport) can improve the postoperative strength by starting rehabilitation immediately after primary anterior cruciate ligament (acl) reconstruction surgery as already shown for patients who underwent total knee arthroplasty. to the investigators knowledge this is the first study analyzing immediate postoperative serious gaming based training with the genusport device based on strength improvement.

the study is designed as a prospective randomized control trial. participants awaiting primary acl reconstruction surgery were recruited at a single tertiary healthcare center between april 2016 and february 2018. an ethical approval has been given by mhh ethic committee and an irb was involved. due to different postoperative treatment protocols and different surgical approaches we could include participants between 13 and 46 years. a computer based randomization was performed by generating a list of randomized numbers which have been provided in sealed envelopes by an independent examiner. the postoperative treatment protocol was apart from the use of the genusport knee trainer identically standardized. the pain management was the same for all patients, none of the participants received a continuous peripheral nerve block. the postoperative physiotherapy protocol included gait training, assisted walking with crutches, active and passive knee mobilization, strength exercises and stair climbing. in the training group each participant was additionally provided with a genusport knee trainer device (prototype plus tablet with software application) with the active knee extension training program for 6 weeks. except of that fact the postoperative protocol was identical in both groups. participant had to train five times daily with the knee trainer starting at the day of surgery.

Eligibility criteria:
inclusion criteria: * patients awaiting primary acl reconstruction surgery * willingness to participate * ability to work with an app based training device exclusion criteria: * additional meniscal suturing * additional collateral ligament repair * additional regenerative cartilage treatment * unwillingness to participate in the study

Keywords: acl rupture return to sports
personalized spine study group registry

Conditions: Scoliosis; Adolescence; Degenerative Disc Disease; Spinal Fusion; Kyphoscoliosis; Pseudoarthrosis of Spine; Spinal Stenosis; Kyphoses, Scheuermann

Summary: as a registry, the primary objective of the study is a data collection initiative. the study will collect clinical and radiographic outcomes of patients implanted with medicrea's psr. the secondary objective is to collect clinical and radiographic outcomes of patients with medicrea hardware as a control cohort to the patient-specific rods.

the registry will follow the patient during their standard of care visits. at each visit, the patient will answer questions about themselves and also fill out patient reported outcome sheets. spinopelvic measurements will be obtained on the x-rays taken. this registry is observational only, and there is no driving hypothesis for data collection. some broad topics of discussion are: 1. outcomes of patients sagittal profile through the pre-operative, plan and post-operative events 2. effectiveness of rod in conjunction with other surgical implants by measurements of fusion assessment and sagittal alignment 3. outcomes of patients in subgroups as defined by surgery performed, comorbidities, radiographic measurement, or other outcome variables 4. rod curvature maintenance over the follow-up period 5. understand the post-operative risks and complications from the pre-operative condition

Eligibility criteria:
inclusion criteria: * patient has been/ will be operated and instrumented with psr from medicrea * patient able to complete a self- administered questionnaires * patient able to consent or assent exclusion criteria: * patient unable to sign an informed consent form * patient unable to complete a self-administered questionnaire * patient is pregnant or planning on becoming pregnant during the duration of their study participation * patient is older than 85 * patient is younger than 10
the clock study - a human dietary intervention study on peripheral circadian clocks and energy metabolism

Conditions: Metabolic Response to Dietary Modification

Summary: this human dietary intervention study with a cross-over design aims to investigate the effect of two different diurnal patterns of meal composition on peripheral circadian clocks and energy metabolism in healthy men.

in this cross-over study, healthy male participants are randomly allocated to one of two study groups: in study group (a) participants consume isocaloric carbohydrate-rich meals (65% carbohydrates; 20% fat; 15% protein) in the morning and fat-rich meals (35% carbohydrate; 50% fat; 15% protein) in the evening for four weeks. after a washout-phase participants consume isocaloric fat-rich meals in the morning and carbohydrate-rich meals in the evening for another four weeks. study group (b) receives the same interventions in the reversed order.

Eligibility criteria:
inclusion criteria: * bmi between 22 kg/m² and 34,9 kg/m² * normal glucose tolerance determined in a 75g-oral glucose tolerance test * impaired fasting glucose determined in a 75g-oral glucose tolerance test * impaired glucose tolerance determined in a 75g-oral glucose tolerance test exclusion criteria: * shift workers or history of shift work * men suffering from diseases or conditions that might influence the outcome of the study. of special interest are diseases that influence body weight regulation (enteropathy, malabsorption, hepatopathy, renal disease, endocrine disorders, diabetes mellitus, eating disorders, heart disease etc.). also men suffering from coagulopathy, apoplexy and myocardial infarction are excluded from the study. * men suffering from psychiatric disease * planned changes in physical activity during the study * participation in other clinical studies within the last three months * weight changes \> 2 kg within 2 months prior to screening day * men unable to give an informed consent * men unable to engage in the dietary interventions * men following a special diet
biomarker study in bone marrow samples from patients with t-cell acute lymphoblastic leukemia

Conditions: Leukemia

Summary: rationale: studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research study is studying biomarkers in bone marrow samples from patients with t-cell acute lymphoblastic leukemia.

objectives: * to confirm an association between induction failure (if) status predicted by a previously identified 116-member genomic classifier and actual induction therapy outcome observed on cog study aall0434. * to explore whether there is an association between early relapse (as defined by bone marrow or extramedullary relapse within 18 months of diagnosis) predicted by previously identified 5-member (primary) and 57-member (secondary) genomic classifiers, and actual relapse status at 18 months on cog study aall0434. (exploratory) outline: rna from cryopreserved bone marrow samples are analyzed for gene expression by microarray methods. samples are then compared with the 116-member genomic classifier.

Eligibility criteria:
disease characteristics: * newly diagnosed t-cell acute lymphoblastic leukemia * cryopreserved bone marrow from the children oncology group (cog) cell bank of patients enrolled on cog-aall03b1 and cog-aall0434, including the following: * 30 samples from patients who had \> 25% bone marrow blasts at day 29 (induction failure \[if\] cases) * samples of cases of bone marrow and/or cns relapse occurring within the first 18 months of treatment * random samples of 105 non-if cases who achieved remission at the end of induction therapy (at least 18 months) patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: adult acute lymphoblastic leukemia in remission childhood acute lymphoblastic leukemia in remission recurrent adult acute lymphoblastic leukemia recurrent childhood acute lymphoblastic leukemia t-cell adult acute lymphoblastic leukemia t-cell childhood acute lymphoblastic leukemia
monitoring bleeding of patients using noac anticoagulation therapy in proximal femoral fracture internal fixation surgery without waiting. we measure bleeding in surgery and the levels of noac drug in blood. we will try to compare to regular pateints later

Conditions: Osteoperosis; Femoral Neck Fractures; Anticoagulant Therapy

Summary: until today we waited at least 24 hours before surgery of femoral neck fractures in patients who take anticouagolation . in our new reasearch we belive that patients who take noac can go under surgery earlier with minimal risk


Eligibility criteria:
inclusion criteria: above 18 y.o femoral neck fracture noac capable of making inform consent primary surgery - exclusion criteria: * under 18 y.o * anti platelet therapy (aspirin is not included) * creatinine clearance under 50 * active anti cancer therapy * itp patients * non capable of making inform consent * patients which decide not to proceed with the expeirment
nicotine and cannabis vape labeling experiment - spring 2025

Conditions: Vaping; Adolescent; Electronic Cigarette Use; Nicotine; Cannabis

Summary: this study assesses how the ways in which nicotine and cannabis vaping devices are labeled impact use susceptibility, anticipated effects, and health harm.

the primary objectives of the study: (1) determine whether different device labels with the contained substance (nicotine or cannabis) affect adolescent use susceptibility, anticipated effects or impairment, and perceived health harms; (2) determine whether device color/product flavor differentially impact the study outcomes.

Eligibility criteria:
inclusion criteria: * participants must be enrolled in a partnering high school. exclusion criteria: * participants who cannot independently understand study consent and the study surveys are ineligible.

Keywords: vaping device product labeling use susceptibility perceived harm nicotine cannabis
medical students' evaluation of dyslipidemia and lipoprotein(a) study

Conditions: Insight Into the Prevalence of Elevated Lp(a) Among Greek Medical Students

Summary: this cross-sectional study aims to determine the prevalence of elevated lp(a) levels among volunteer medical students at the faculty of medicine, university hospital of ioannina, greece. data collected will include demographic information, family and medical history, as well as lifestyle habits, and the study aims to provide valuable insights into the prevalence of elevated lp(a) among greek medical students.

lipoprotein(a) \[lp(a)\] has emerged as a prevalent monogenetic cardiovascular risk factor globally. despite its significance, clinical attention for elevated lp(a) is suboptimal. this cross-sectional study aims to determine the prevalence of elevated lp(a) levels among volunteer medical students at the faculty of medicine, university hospital of ioannina, greece, as well as gather data on the demographic characteristics and medical history of this population. statistical analysis will assess lp(a) levels, prevalence, and associations with demographic and cardiovascular risk factors. the study aims to provide valuable insights into the prevalence of elevated lp(a) among greek medical students, emphasizing the importance of awareness, early diagnosis, and management of this cardiovascular risk factor.

Eligibility criteria:
inclusion criteria: * medical students at the faculty of medicine, university hospital of ioannina, greece. exclusion criteria: * inability/unwillingness to give informed consent
ascent: androgen independent prostate cancer study of calcitriol enhancing taxotere

Conditions: Prostate Cancer

Summary: the purposes of this study are to determine if dn-101 plus taxotere lowers psa levels, delays or limits disease progression and is safe with minimal side effects.

dn-101 is an investigational drug that has not been approved by the u.s. food and drug administration (fda). it is a newly formulated pill that contains high amounts of calcitriol, a naturally occurring hormone and the biologically active form of vitamin d. administration of dn-101 results in much higher blood levels of calcitriol than the body can produce from dietary vitamin d or vitamin d supplements. these higher levels of calcitriol are associated with anti-cancer effects in laboratory models of human cancer. laboratory models also indicate that calcitriol has synergy with many commonly used chemotherapeutic agents used to treat cancer. calcitriol, at very low doses, is currently approved for use in patients with chronic kidney failure. dn-101 was specifically designed for cancer and contains 30 times the amount of calcitriol found in the calcitriol pill commercially available today. in order to take an amount of calcitriol equivalent to 1 dn-101 pill, cancer patients would need to swallow 30 pills of the approved, low dose formulation. dn-101 represents a breakthrough in the use of calcitriol in the clinic, because it contains high concentrations of calcitriol and makes it more feasible for patients to stay on regimen.

Eligibility criteria:
* three rising psa measurements or a new metastatic lesion * adequate liver and kidney function * ongoing hormonal therapy * no hospitalization for angina, heart attack or congestive heart failure within the last 12 months * no kidney stones in the last 5 years

Keywords: prostate cancer androgen independent prostate cancer
immune restoration by lipoic acid in aids

Conditions: Acquired Immunodeficiency Syndrome; HIV Infections

Summary: the purpose of this study is to determine the immunomodulatory and antiviral effects of the glutathione-restoring dithiol, alpha lipoic acid (ala) in hiv-infected persons unresponsive to highly active antiretroviral treatment (haart).

aids is characterized by infection with hiv which leads to collapse of the immune system. although highly active antiretroviral therapy (haart) has contributed significantly to lowering morbidity and mortality from aids, antiretroviral drugs do not fully restore the immune system and patients often fail multi-drug treatment. hence, there is a need for alternative/complementary medicine (cam) that can restore an immune system ravaged by hiv/aids. to address this need, investigators have formed a multidisciplinary collaboration to evaluate and demonstrate utility of natural immune-based modulators in ethnically diverse patients with hiv/aids. the long-term goal of this proposal is to develop a cam therapy to facilitate immune reconstitution and hiv eradication following cessation of antiretroviral treatment or concurrent with continued antiretroviral treatment. it is based on the premise of a widespread deficiency of glutathione (gsh), vital to lymphocyte function, in patients with hiv/aids. the proposed project will study the immunomodulatory and antiretroviral effects of a dietary antioxidant, alpha-lipoic acid (ala), which is known to efficiently boost systemic gsh. in this study, hiv-infected adults unresponsive to haart (i.e. those with persistent cd4+ count \> 50 cells/mm3, viral load\> 10,000 copies/cc) will be randomized into a treatment or a control arm. the treatment group will be given 300 mg ala thrice daily for 6 months and the control group will receive inert placebo. studies performed at baseline and at 2,4, and 6 months will include estimation of cd4+ count, hiv rna, t-cell reactivity in vitro and whole blood gsh level. significance of changes from baseline parameters will be analyzed by t-tests. the proposed research will show whether gsh augmentation by ala increases cd4+ cell number and t cell function and reduces viral load in subjects unresponsive to antiretroviral therapy.

Eligibility criteria:
inclusion criteria: * hiv-positive status * haart non-responsiveness as defined by 1) previous experience with at least 2 different protease inhibitors plus nucleoside analogs; 2) viral load of \>10,000 copies/cc and cd4+ cell count \>50 x 1000 cells/liter at time of enrollment exclusion criteria: * diabetic patients * pregnant women * asthmatic patients * severely thiamine-deficient persons (e.g. alcoholics and those with polyneuritis) * history of supplementing on excessive amounts of n-acetylcysteine, glutathione or other antioxidant supplements, during the 2 months prior to study entry.

Keywords: complementary therapies immune restoration hiv infection aids haart non-responsiveness glutathione restoration lipoic acid dithiol
active cycle of breathing technique verses breathing exercises in post icu covid-19 patients

Conditions: Post Covid-19 Patients

Summary: the experiment was randomized and controlled. to create groups a and b,48 individuals were selected by sample selection criteria. evaluation of oxygen saturation and pulmonary function tests were taken using a pulse oximeter and spirometer. group a got chest physiotherapy with breathing exercises and acbt whereas group b got chest physiotherapy with breathing exercises. the treatment took 15-30 minutes and consisted of one session per day, treatment was given 6 days a week for up to 2 weeks and examined by using spss 22.

the experiment was randomized and controlled. to create groups a and b,48 individuals were selected by sample selection criteria. evaluation of oxygen saturation and pulmonary function tests were taken using a pulse oximeter and spirometer. group a got chest physiotherapy with breathing exercises and acbt whereas group b got chest physiotherapy with breathing exercises. the treatment took 15-30 minutes and consisted of one session per day, treatment was given 6 days a week for up to 2 weeks and examined by using spss 22.

Eligibility criteria:
inclusion criteria: * adult population * age limit 18 -50 * all patients positive with confirmed covid-19 by polymerase chain reaction (pcr) test and chest computed tomography scan (ct-scan) exclusion criteria: * the patient cannot take part in the trial if they have any kind of muscular-skeletal issue. * covid-19-related intubation history * a clear clinical mental or cognitive disability of any kind. * patient on ventilator